Checkpoint Inhibitor and Cytokine Secretion Assays
Two of the top revenue generating drugs on the market involve immune checkpoint inhibition for cancer treatment. The drugs are Opdivo (Bristol Myers Squibb) and Keytruda (Merck), and represent a total 2018 revenue of 15 billion dollars. The mechanism of action of these drugs is to block the binding of PD-L1 expressed on tumor cells to the PD-1 receptor of T cells. This mechanism enables T cell recognition of the tumor for what it is and initiate an immune response. This response involves the recruitment of immune cells to the tumor site and the release of a wide variety of cytokines to control the response.
There are a wide range of immunoassay technologies and kits for the quantification of these markers from serum or blood plasma. These include the standard ELISA platforms, including more recent technologies for rapid screening using “mix and read” workflows and classical ELISpot assays. Agilent BioTek provides microplate readers and washers that can be used for a broad range of sample throughput.
Application Notes
- Multiplexed Assay for IL-6 Secretion and Cell Viability Using an Epithelial Ovarian Cancer Cell Line
- Stimulation of Human Peripheral Blood Mononuclear Cells
For Research Use Only. Not for use in diagnostic procedures.
RA44218.4051388889